Management

Officers, Directors and Principal Investigators

Prior to Angion, Dr. Venkatesan served as President and Director of Alpine Immune Sciences (ALPN), which he co-founded as a Managing Partner of Alpine BioVentures. Previously, Dr. Venkatesan was the founder and portfolio manager of Ayer Capital, a global healthcare fund. Prior to that, he served as a director at Brookside Capital, part of Bain Capital, where he co-managed healthcare investments. He was also a consultant at McKinsey & Co. and a venture investor with Patricof & Co. Ventures (now Apax Partners). He received his M.D. from the University of Pennsylvania School of Medicine, his M.B.A. from the Wharton School of the University of Pennsylvania, and his B.A. from Williams College.
Itzhak Goldberg, MD, FACR, is Angion’s Founder and its past President and CEO. Previously, he was a faculty member at Harvard Medical School, Boston, Mass., Radiation Oncologist-in-Chief for the North Shore-Long Island Jewish Health System (now Northwell Health), New Hyde Park, NY, Professor at the Albert Einstein College of Medicine, Bronx, NY. He is a Fellow of the American College of Radiology. Prior to that, Dr. Goldberg was a Research Fellow and recipient of the William Milton Award at Harvard Medical School and a Research Affiliate at MIT. Dr. Goldberg has made seminal contributions in the area of hepatocyte growth factor signaling, apoptosis and angiogenesis, has published extensively in these areas and is an inventor on numerous patents.
Dr. Yamin received his Ph.D. from The Rockefeller University, and has worked in small biopharma companies including Alteon, Mojave Therapeutics, Warren Pharmaceuticals and Araim Pharmaceuticals, in the areas of intellectual property, discovery and pre-clinical development. He is also a registered patent agent.
Dr. Narayan received his doctorate from The Ohio State University and conducted postdoctoral research at University of Wisconsin-Madison. He is an expert in models of acute tissue injury and chronic degenerative disease and is the recipient of multiple NIH, DoD and NSF translational research awards. He is a member of the Baltimore PKD Organization and an expert panelist for the European Society of Translational Medicine.
Dr. Oehlen received his doctorate from the University of Amsterdam in the Netherlands and was a post doctoral fellow at Rockefeller University in New York City. He has had over 10 years of industry experience working previously at Cadus Pharmaceuticals and OSI Pharmaceuticals. Dr. Oehlen has expertise in the areas of drug development and pulmonary diseases.
Mr. Goldberg leads business developments efforts for Angion Biomedica. Primary responsibilities include capital raising, strategic partnerships, and licensing agreements. Mr. Goldberg previously founded Broadfire Technologies, a thin client architecture company run out of MIT’s Lab for Computer Science (LCS) under Dr. Michael Dertouzos. He has also worked in equities and investment banking for multiple financial institutions, including Goldman Sachs, in the United States and abroad. Mr. Goldberg received his MBA from Columbia Business School with a concentration in corporate finance in 2005.
Dr. Paka received her Ph.D. degree from Osmania University, India, and pursued post-doctoral research on atherosclerotic cardiovascular disease for four years at Columbia University, NY. With extensive experience in the areas of cell biology and biochemistry, she plays a major role in the establishment of acute and chronic preclinical models to evaluate candidate compounds in organ-specific models of tissue injury. She is also a recipient of several translational research NIH awards.
Dr. An-Hu Li trained at the National Institutes of Health and Harvard University (under Nobel Laurate, Prof. EJ Corey). He brings world-class experience with small molecule modulators of biological targets for use in disease. During his tenure with OSI Pharmaceuticals and Astellas, Dr. Li brought five novel compounds from discovery into clinical development and has multiple patents and publications to his name.
Dr. Ali received his PhD from the University of Houston in pharmacology, and post-doctoral training at Auburn University, Univ. of Houston and University of Oklahoma Health Sciences Center, in cardiovascular and renal physiology with special focus on heart failure, hypertension and renal dysfunction. He has extensive experience in assessing novel drugs for cardio-renal disorders.
Patrick Simms brings over 20 years of protocol to publication experience with clinical trials and regulatory affairs; he has managed complex clinical trial operations including Phase 1 proof-of-concept and characterization studies, Phase 2 trials and a number of global Phase 3 clinical trials. Patrick is a milestone- driven proven leader who maximizes program speed by aligning team and company goals and balances program design with intelligent risk management, experiential problem solving and strategic flexibility. He leverages scientific background, experience, business acumen and sensitive communication skills to support a consensus driven atmosphere across multilayer organizational matrices. Leadership positions at a number of pharmaceutical companies including Biodel, Mannkind, and Chenwerth coupled with hands-on experience managing CMC, Device, Preclinical, Clinical and Regulatory programs has resulted in > 30 ANDA, ANADA and 505b2 drug product submissions. Patrick was instrumental in the development and approval of TOBI® Inhale indicated for the management of cystic fibrosis patients with P. aeruginosa, TRISENOX® indicated for induction of remission and consolidation in patients with acute promyelocytic leukemia and AFREEZA® indicated to improve glycemic control in adult patients with diabetes mellitus.